ArticleClinical genitourinary cancer2022
MRI-Detectability of Clinically Significant Prostate Cancer Relates to Oncologic Outcomes After Prostatectomy.
Article in Clinical genitourinary cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Refining biopsy strategies stratified by PI-RADS score in men: a systematic review and network meta-analysis.Nature communications · 2026Pooled it
- PSMA PET: the answer to MRI-occult prostate cancer… or another mirage?European radiology · 2026Review
- [Prevention instead of remediation-screening, lifestyle factors, and prostate care 2.0-transition of urology to healthcare coach : Holistic approach to prostate health].Urologie (Heidelberg, Germany) · 2026Review
- Multiparametric MRI findings, PI-RADS scores, and gleason scores in prostate cancer patients at Kumasi, Ghana: a cross-sectional analysis.BMC medical imaging · 2026Article
- New kids on the block: MRI guided transrectal focused US, TULSA, focal laser ablation, histotripsy - a comprehensive review.Prostate cancer and prostatic diseases · 2026Review
- Prognostic value of MR visibility/invisibility in men on Active Surveillance.Prostate cancer and prostatic diseases · 2025Article
- Imaging in focal therapy: advanced ultrasound imaging and mpMRI-a comprehensive review.Prostate cancer and prostatic diseases · 2025Review
- Preoperative MRI-based predictive model for biochemical recurrence following radical prostatectomy.Abdominal radiology (New York) · 2025Article
- Should systematic prostatic biopsies be discontinued?Prostate cancer and prostatic diseases · 2025Review
- Applying Focal Therapy to Lesions Detected via Magnetic Resonance Imaging: Delivering Cancer Ablation Beyond the Visibility Phenomenon.European urology open science · 2025Article
- MRI-based virtual pathology of the prostate.Magma (New York, N.Y.) · 2024Review
- Management of Patients With a Negative Multiparametric Prostate MRI Examination:AJR. American journal of roentgenology · 2024Review
- American College of Radiology initiatives on prostate magnetic resonance imaging quality.European journal of radiology · 2023Review
- PI-RADS: Where Next?Radiology · 2023Review
- Novel radiomic analysis on bi-parametric MRI for characterizing differences between MR non-visible and visible clinically significant prostate cancer.European journal of radiology open · 2023Article
Corrections and comments
- Commented on by
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
Abstract
INTRODUCTION/
backgroundMagnetic resonance imaging (MRI) misses a proportion of "clinically significant" prostate cancers (csPC) as defined by histopathology criteria. The aim of this study was to analyze whether long-term oncologic outcomes differ between MRI-detectable and MRI-occult csPC. PATIENTS AND
methodsRetrospective analysis of 1449 patients with pre-prostatectomy MRI and csPC on prostatectomy specimens (ie, Grade group ≥2 or extraprostatic spread) between 2001-2006. T2-weighted MRIs were classified according to the Prostate Imaging Reporting and Data System into MRI-occult (categories 1, 2), MRI-equivocal (category 3), and MRI-detectable (categories 4, 5). Cumulative incidence of biochemical recurrence (BCR), metastatic disease, and cancer-specific mortality, estimated with competing risk models. The median follow-up in survivors was 11.0 years (IQR: 8.9-13.1).
resultsIn 188 (13%) cases, csPC was MRI-occult, 435 (30%) MRIs were equivocal, and 826 (57%) csPC were MRI-detectable. The 15-year cumulative incidence [95% CI] of BCR was 8.3% [2.2, 19.5] for MRI-occult cases, 17.4% [11.1, 24.8] for MRI-equivocal cases, and 43.3% [38.7, 47.8] for MRI-detectable cases (P < .001). The cumulative incidences of metastases were 0.61% [0.06, 3.1], 3.5% [1.5, 6.9], and 19.6% [15.4, 24.2] for MRI-occult, MRI-equivocal, and MRI-detectable cases, respectively (P < .001). There were no deaths from prostate cancer observed in patients with MRI-occult csPC, compared to an estimated 1.9% [0.54, 4.9], and 7.1 % [4.5, 10.6] for patients with MRI-equivocal and MRI-detectable cancer, respectively (P < .001).
conclusionOncologic outcomes after prostatectomy for csPC differ between MRI-occult and MRI-detectable lesions. Judging the clinical significance of a negative prostate MRI based on histopathologic surrogates alone might be misleading. MICROABSTRACT: Among 1449 patients with pre-prostatectomy MRI and clinically significant prostate cancer on prostatectomy histopathology, MRI-occult cancers (n = 188, 13%) were less likely to recur biochemically (8% vs. 43%, P < .001), metastasize (0.6% vs. 20%, P < .001), or lead to prostate cancer mortality (0% vs. 7%, P < .001) than MRI-detectable cancers (n = 826, 57%). MRI-occult cancers constitute a prognostically distinct subgroup among higher-grade prostate cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.